DBVT - Why DBV Technologies Stock Is Jumping Today
Shares of DBV Technologies (NASDAQ: DBVT) were jumping 8.9% as of 12:06 p.m. EDT on Monday after rising as much as 11.9% earlier in the day. The solid gain followed the company's announcement that it will present new clinical study results for experimental peanut allergy drug Viaskin Peanut (DBV712) at the 250-microgram dose in children at the American College of Allergy, Asthma & Immunology (ACAII) Annual Scientific Meeting scheduled for Nov. 4 through Nov. 8.
Investors appear to be anticipating that DBV will provide good news at the ACAII meeting that starts later this week. They're likely basing their optimism on comments from DBV Technologies chief medical officer Pharis Mohideen. In the press release announcing the ACAII presentation, Mohideen said, "These data presented at ACAII contribute to our understanding of and excitement for the potential real-world use of Viaskin Peanut, if approved."
Image source: Getty Images.
For further details see:
Why DBV Technologies Stock Is Jumping Today